Eli Lilly Raises Profit Forecast
This is a Zepbound news story, published by Yahoo Finance, that relates primarily to Eli Lilly news.
Zepbound news
For more Zepbound news, you can click here:
more Zepbound newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Zepbound sales. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest year profit forecast news, Lilly news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
annual profit forecastReuters
•Eli Lilly raises annual forecasts as weight-loss drug quarterly sales cross $1 billion
80% Informative
Shares of Eli Lilly rose more than 9% in premarket trading, with sales of its weight-loss drug, Zepbound , crossing $1 billion for the first time in a quarter .
The strong sales number for the drug comes a day after Danish rival Novo Nordisk reported a rare miss on quarterly sales of Wegovy .
VR Score
90
Informative language
95
Neutral language
79
Article tone
formal
Language
English
Language complexity
41
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links